Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis

Journal of Hepatology

Volumn 46, Issue 3, 2007, Pages 420-431

  Bonkovsky, Herbert L ^a   Snow, Kristin K ^b   Malet, Peter F ^c   Back Madruga, Carla ^d   Fontana, Robert J ^e   Sterling, Richard K ^f   Kulig, Clark C ^g   Di Bisceglie, Adrian M ^h   Morgan, Timothy R ⁱ   Dienstag, Jules L ^j   Ghany, Marc G ^k   Gretch, David R ^l  

^a The Liver Biliary Pancreatic Center   (United States)

^b NEW ENGLAND RESEARCH INSTITUTES   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^f VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^g UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^h SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j MASSACHUSETTS GENERAL HOSPITAL   (United States)

^k NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^l UNIVERSITY OF WASHINGTON   (United States)

more..

Author keywords

Cirrhosis; Fibrosis; Health related quality of life; Hepatitis; Sexual functioning; Sustained virological response; Viral type C

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; FEMALE; HEPATITIS C; HUMAN; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RELAPSE; SCORING SYSTEM; SEXUAL HEALTH; VIROLOGY;

ADULT; ANTIVIRAL AGENTS; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; HEALTH STATUS; HEALTH SURVEYS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; QUALITY OF LIFE; RIBAVIRIN; SEXUAL BEHAVIOR; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL; TREATMENT OUTCOME;

EID: 33846828559     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2006.10.009     Document Type: Article

References (50)

1. Liang T.J., Rehermann B., Seeff L.B., and Hoofnagle J.H. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 132 (2000) 296-305
2. Armstrong G.L., Wasley A., Simard E.P., McQuillan G.M., Kuhnert W.L., and Alter M.J. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 144 (2006) 705-714
3. Hoofnagle J.H. Hepatitis C: the clinical spectrum of disease. Hepatology 26 3 Suppl. 1 (1997) 15S-20S
4. Di Bisceglie A.M., and Hoofnagle J.H. Optimal therapy of hepatitis C. Hepatology 36 5 Suppl. 1 (2002) S121-S127
5. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002-June 10-12, 2002. Hepatology 2002;36(5 Suppl. 1):S3-20.
6. Strader D.B., Wright T., Thomas D.L., and Seeff L.B. Diagnosis, management, and treatment of hepatitis C. Hepatology 39 (2004) 1147-1171
7. Carithers Jr. R.L., Sugano D., and Bayliss M. Health assessment for chronic HCV infection: results of quality of life. Dig Dis Sci 41 12 Suppl. (1996) 75S-80S
8. Manns M. Autoimmune hepatitis. In: Schiff E.R., Sorrell M.F., and Maddrey W.C. (Eds). Schiff's diseases of the liver. 9th ed. (2003), Lippincott Williams & Wilkins, Philadelphia, PA 1001-1018
9. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Goncales Jr. F.L., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347 (2002) 975-982
10. Hadziyannis S.J., Sette Jr. H., Morgan T.R., Balan V., Diago M., Marcellin P., et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140 (2004) 346-355
11. Bonkovsky H.L., and Woolley J.M. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group. Hepatology 29 (1999) 264-270
12. McHutchison J.G., Ware Jr. J.E., Bayliss M.S., Pianko S., Albrecht J.K., Cort S., et al. The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity. J Hepatol 34 (2001) 140-147
13. Neary M.P., Cort S., Bayliss M.S., and Ware Jr. J.E. Sustained virologic response is associated with improved health-related quality of life in relapsed chronic hepatitis C patients. Semin Liver Dis 19 Suppl. 1 (1999) 77-85
14. Rasenack J., Zeuzem S., Feinman S.V., Heathcote E.J., Manns M., Yoshida E.M., et al. Peginterferon alpha-2a (40 kDa) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis C. Pharmacoeconomics 21 (2003) 341-349
15. Davis G.L., Balart L.A., Schiff E.R., Lindsay K., Bodenheimer Jr. H.C., Perrillo R.P., et al. Assessing health-related quality of life in chronic hepatitis C using the Sickness Impact Profile. Clin Ther 16 (1994) 334-343
16. Chou R., Clark E.C., and Helfand M. Screening for hepatitis C virus infection: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 140 (2004) 465-479
17. Hussain K.B., Fontana R.J., Moyer C.A., Su G.L., Sneed-Pee N., and Lok A.S. Comorbid illness is an important determinant of health-related quality of life in patients with chronic hepatitis C. Am J Gastroenterol 96 (2001) 2737-2744
18. Fontana R.J., Moyer C.A., Sonnad S., Lok A.S.F., Sneed-Pee N., Walsh J., et al. Comorbidities and quality of life in patients with interferon-refractory chronic hepatitis C. Am J Gastroenterol 96 (2001) 170-178
19. Lee W.M., Dienstag J.L., Lindsay K.L., Lok A.S., Bonkovsky H.L., Shiffman M.L., et al. Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials 25 (2004) 472-492
20. Shiffman M.L., Di Bisceglie A.M., Lindsay K.L., Morishima C., Wright E.C., Everson G.T., et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 126 (2004) 1015-1023
21. Ishak K., Baptista A., Bianchi L., Callea F., De G.J., Gudat F., et al. Histological grading and staging of chronic hepatitis. J Hepatol 22 (1995) 696-699
22. Beck AT. Beck Depression Inventory. San Antonio, TX; 1987.
23. Beck A.T., Steer R.A., and Brown G.K. The Psychological Corporation (1996), Harcourt Brace and Company, San Antonio, TX
24. Ware J.E., Snow K.K., Kosinski M., and Gandek B. SF-36 Health Survey Manual and Interpretation Guide (1993), The Health Institute, New England Medical Center, Boston, MA
25. Ware J.E., Kosinski M., and Keller S.D. SF-36 Physical and Mental Summary Scales: A User's Manual (1994), The Health Institute, New England Medical Center, Boston, MA
26. Stewart A.L., Hays R.D., and Ware Jr. J.E. The MOS short-form general health survey. Reliability and validity in a patient population. Med Care 26 (1988) 724-735
27. McHorney C.A., Ware Jr. J.E., Lu J.F., and Sherbourne C.D. The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care 32 (1994) 40-66
28. McHorney C.A., Ware Jr. J.E., and Raczek A.E. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 31 (1993) 247-263
29. Ware Jr. J.E., and Sherbourne C.D. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30 (1992) 473-483
30. Jenkinson C., Lawrence K., McWhinnie D., and Gordon J. Sensitivity to change of health status measures in a randomized controlled trial: comparison of the COOP charts and the SF-36. Qual Life Res 4 (1995) 47-52
31. Stucki G., Daltroy L., Katz J.N., Johannesson M., and Liang M.H. Interpretation of change scores in ordinal clinical scales and health status measures: the whole may not equal the sum of the parts. J Clin Epidemiol 49 (1996) 711-717
32. Wolinsky F.D., Wan G.J., and Tierney W.M. Changes in the SF-36 in 12 months in a clinical sample of disadvantaged older adults. Med Care 36 (1998) 1589-1598
33. Coakley E.H., Kawachi I., Manson J.E., Speizer F.E., Willet W.C., and Colditz G.A. Lower levels of physical functioning are associated with higher body weight among middle-aged and older women. Int J Obes Relat Metab Disord 22 (1998) 958-965
34. Hunt C.M., Dominitz J.A., Bute B.P., Waters B., Blasi U., and Williams D.M. Effect of interferon-alpha treatment of chronic hepatitis C on health-related quality of life. Dig Dis Sci 42 (1997) 2482-2486
35. Foster G.R., Goldin R.D., and Thomas H.C. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 27 (1998) 209-212
36. Fontana R.J., Hussain K.B., Schwartz S.M., Moyer C.A., Su G.L., and Lok A.S. Emotional distress in chronic hepatitis C patients not receiving antiviral therapy. J Hepatol 36 (2002) 401-407
37. Perrillo R., Rothstein K.D., Rubin R., Alam I., Imperial J., Harb G., et al. Comparison of quality of life, work productivity and medical resource utilization of peginterferon alpha 2a vs the combination of interferon alpha 2b plus ribavirin as initial treatment in patients with chronic hepatitis C. J Viral Hepat 11 (2004) 157-165
38. Wessely S., and Pariante C. Fatigue, depression and chronic hepatitis C infection. Psychol Med 32 (2002) 1-10
39. Hauser W., Zimmer C., Schiedermaier P., and Grandt D. Biopsychosocial predictors of health-related quality of life in patients with chronic hepatitis C. Psychosom Med 66 (2004) 954-958
40. Skinner H.A., and Sheu W.J. Reliability of alcohol use indices. The Lifetime Drinking History and the MAST. J Stud Alcohol 43 (1982) 1157-1170
41. Ostapowicz G., Watson K.J., Locarnini S.A., and Desmond P.V. Role of alcohol in the progression of liver disease caused by hepatitis C virus infection. Hepatology 27 (1998) 1730-1735
42. Dufour M.C. What is moderate drinking? Defining "drinks" and drinking levels. Alcohol Res Health 23 (1999) 5-14
43. Thalji L, Haggerty CC, Rubin R, Berckmans TR, Pardee FL. 1990 National Survey of Functional Health Status: Final Report. Chicago, IL: National Opinion Research Center; 1990.
44. Falck-Ytter Y., Kale H., Mullen K.D., Sarbah S.A., Sorescu L., and McCullough A.J. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med 136 (2002) 288-292
45. Strader D.B. Understudied populations with hepatitis C. Hepatology 36 5 Suppl. 1 (2002) S226-S236
46. Afdhal N.H., Dieterich D.T., Pockros P.J., Schiff E.R., Shiffman M.L., Sulkowski M.S., et al. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology 126 (2004) 1302-1311
47. Rosen R.C. Measurement of male and female sexual dysfunction. Curr Psychiatry Rep 3 (2001) 182-187
48. Zickmund S., Hillis S.L., Barnett M.J., Ippolito L., and LaBrecque D.R. Hepatitis C virus-infected patients report communication problems with physicians. Hepatology 39 (2004) 999-1007
49. Zickmund S., Ho E.Y., Masuda M., Ippolito L., and LaBrecque D.R. "They treated me like a leper". Stigmatization and the quality of life of patients with hepatitis C. J Gen Intern Med 18 (2003) 835-844
50. Danoff A., Khan O., Wan D.W., Hurst L., Cohen D., Tenner C.T., et al. Sexual dysfunction is highly prevalent among men with chronic hepatitis C virus infection and negatively impacts quality of life. Am J Gastroenterol 101 (2006) 1235-1243